US FDA approves J&J's bladder cancer treatment

US FDA approves J&J's bladder cancer treatment

(Reuters) -The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative to surgically remove the organ.

J&J’s ‘pretzel’ drug-device therapy wins US approval for certain bladder cancers

Johnson & Johnson has secured FDA approval for a drug-device approach for bladder cancer that could spare patients from having to get their bladders surgically removed. The company’s TAR-200 was greenlit for non-muscle invasive bladder ...

FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

US FDA approves J&J’s bladder cancer treatment - Regional Media News

(Reuters) -The U.S. Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative to surgically remove the organ. The drug release system, branded as Inlexzo, was approved for patients with a type of high-risk non-muscle invasive bladder cancer who did not respond to treatment with Bacillus Calmette-Guerin (BCG) therap…